|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Among the processes involved in the breast tumor microenvironment, angiogenesis and inflammation play a central role, and the main factors of these processes are the vascular endothelial growth factor (VEGF), cyclooxygenase 2 (COX-2) and macrophages.
|
29609579 |
2018 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Inducible cyclooxgenase-2 (COX-2) is commonly overexpressed in breast tumors and is a target for cancer therapy.
|
28666869 |
2017 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
COX-2 modulates mammary tumor progression in response to collagen density.
|
27000374 |
2016 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These data suggest that downregulation of RhoGDI could be a critical mechanism of breast tumor development, which may involve the hyperactivation of Rho GTPases and upregulation of COX-2 activity.
|
26416248 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, these results showed that LV-COX-2 combination with TAM is a potential drug candidate for treatment of breast tumors expressing high levels of VEGF.
|
24535190 |
2014 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
|
24590894 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
|
21683430 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Overall, these data identify a new p130Cas/Cyclooxygenase-2 axis as a crucial element in the control of breast tumor plasticity, opening new therapeutic strategies leading to inhibition of these pathways in aggressive breast carcinoma.
|
23098208 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To elucidate the mechanisms by which exacerbated COX2 expression potentiates metastasis we genetically manipulated non-metastatic mammary tumor cells (TM40D) to over-express COX2 (TM40D-COX2).
|
23029485 |
2012 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
By immunocytochemistry, Western blotting and flow cytometry analysis, oestrogen treatment of R2d cells was found to induce many important effects related to breast carcinogenesis, namely: (i) the emergence of a subpopulation of cells expressing CD44+/high/CD24-/low breast tumour stem cell markers; (ii) the induction of EMT (epithelial-to-mesenchymal transition); (iii) the acquisition of metastatic ability; and (iv) the expression of COX-2 (cyclo-oxygenase-2) through a CD44-mediated mechanism.
|
19895368 |
2010 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Up-regulation of COX-2 in ER-negative and HER2-positive breast tumors is associated with Akt pathway activation and is a marker of poor outcome.
|
21078168 |
2010 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High levels of the cyclooxygenase-2 (COX-2) protein have been associated with invasion and metastasis of breast tumors.
|
18386173 |
2009 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Cyclooxygenase-2 expression during immortalization and breast cancer progression.
|
18199541 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
|
18190720 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The malignant phenotype of breast cancer cells is reduced by COX-2 silencing.
|
18953425 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Glucocorticoid receptor changes its cellular location with breast cancer development.
|
17952860 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.
|
18334709 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.
|
18498876 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Tpl-2/Cot and COX-2 in breast cancer.
|
18795070 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Pathological analysis demonstrated that COX-2 overexpression was associated with CCR7, EP2, and EP4 expressions in breast tumor tissues.
|
18319253 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
|
18262731 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Cyclooxygenase-2 (COX-2) is associated with breast tumour progression.
|
18469157 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS.
|
18192694 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
[The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer].
|
18509974 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.
|
18498876 |
2008 |